Canine Atopic Dermatitis - Global Strategic Business Report

Global Canine Atopic Dermatitis Market to Reach $2.5 Billion by 2030

The global market for Canine Atopic Dermatitis estimated at US$1.2 Billion in the year 2022, is projected to reach a revised size of US$2.5 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2022-2030. Glucocorticoids, one of the segments analyzed in the report, is projected to record 9.8% CAGR and reach US$1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Antihistamines segment is readjusted to a revised 9.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $336.3 Million, While China is Forecast to Grow at 15% CAGR

The Canine Atopic Dermatitis market in the U.S. is estimated at US$336.3 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$636.3 Million by the year 2030 trailing a CAGR of 15% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 8.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Select Competitors (Total 42 Featured) -

• AB Science
• Boehringer Ingelheim
• Ceva
• Elanco
• Elanco Animal Health
• indred Biosciences Inc.
• Kindred Biosciences
• Novartis
• Toray Industries
• Virbac
• Zoetis

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year